147 related articles for article (PubMed ID: 38351273)
1. Proteinuria frequency and subsequent renal dysfunction in bevacizumab-treated patients: a single center, retrospective, observational study.
Kataoka S; Nishikawa Y; Funakoshi T; Horimatsu T; Sakuragi M; Uchino E; Hiragi S; Yamamoto S; Sakai K; Matsubara T; Yanagita M; Muto M
Int J Clin Oncol; 2024 Apr; 29(4):398-406. PubMed ID: 38351273
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of Factors Affecting Proteinuria Onset Timing in Patients Treated with Bevacizumab].
Murakami A; Noto K; Ota R; Hirata A
Yakugaku Zasshi; 2022; 142(6):641-649. PubMed ID: 35650084
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal Antivascular Endothelial Growth Factor Therapy May Induce Proteinuria and Antibody Mediated Injury in Renal Allografts.
Cheungpasitporn W; Chebib FT; Cornell LD; Brodin ML; Nasr SH; Schinstock CA; Stegall MD; Amer H
Transplantation; 2015 Nov; 99(11):2382-6. PubMed ID: 25905984
[TBL] [Abstract][Full Text] [Related]
4. Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials.
Lafayette RA; McCall B; Li N; Chu L; Werner P; Das A; Glassock R
Am J Nephrol; 2014; 40(1):75-83. PubMed ID: 25059491
[TBL] [Abstract][Full Text] [Related]
5. Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan.
Tanaka H; Takahashi K; Yamaguchi K; Kontani K; Motoki T; Asakura M; Kosaka S; Yokomise H; Houchi H
Biol Pharm Bull; 2018; 41(4):644-648. PubMed ID: 29607938
[TBL] [Abstract][Full Text] [Related]
6. Plasma endothelin-1 may predict bevacizumab-induced proteinuria in patients with colorectal cancer.
Nihei S; Ikeda T; Aoki T; Murasato F; Yaegashi M; Asahi K; Kudo K
Cancer Chemother Pharmacol; 2023 May; 91(5):427-434. PubMed ID: 37036487
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival and renal dysfunction in a patient with recurrent colorectal cancer treated with Bevacizumab.
Kataoka S; Nishikawa Y; Funakoshi T; Horimatsu T; Kondo N; Matsubara T; Yanagita M; Matsumoto S; Muto M
Clin J Gastroenterol; 2020 Jun; 13(3):316-319. PubMed ID: 31707696
[TBL] [Abstract][Full Text] [Related]
8. Proteinuria with first-line therapy of metastatic renal cell cancer.
Land JD; Chen AH; Atkinson BJ; Cauley DH; Tannir NM
J Oncol Pharm Pract; 2016 Apr; 22(2):235-41. PubMed ID: 25505255
[TBL] [Abstract][Full Text] [Related]
9. Renin-angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis.
Hirai T; Shuji Y; Takiyama M; Hanada K; Itoh T
Cancer Chemother Pharmacol; 2019 Jul; 84(1):195-202. PubMed ID: 31119376
[TBL] [Abstract][Full Text] [Related]
10. Adverse Events Associated With Long-term Treatment of Epithelial Ovarian Cancer With Bevacizumab and Chemotherapy.
Yokoyama Y; Kubo-Kaneda M; Sunada K; Teishikata Y; Kitamura A; Okamoto K; Toriyabe K; Nii M; Yoshida K; Kondo E; Ikeda T
Anticancer Res; 2022 Aug; 42(8):4165-4171. PubMed ID: 35896225
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer: a retrospective study.
Lim AR; Kim JH; Hyun MH; Kim YH; Lee S
Support Care Cancer; 2022 Oct; 30(10):8129-8137. PubMed ID: 35779133
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab safety in Japanese patients with colorectal cancer.
Hatake K; Doi T; Uetake H; Takahashi Y; Ishihara Y; Shirao K
Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors.
Yeh J; Frieze D; Martins R; Carr L
Ann Pharmacother; 2010 Jun; 44(6):1010-5. PubMed ID: 20460557
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
15. Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients.
Tamiya A; Yamazaki K; Boku N; Machida N; Kojima T; Taku K; Yasui H; Fukutomi A; Hironaka S; Onozawa Y
Int J Clin Oncol; 2009 Dec; 14(6):513-7. PubMed ID: 19967487
[TBL] [Abstract][Full Text] [Related]
16. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab-induced proteinuria and its association with antihypertensive drugs: A retrospective cohort study using a Japanese administrative database.
Kiyomi A; Koizumi F; Imai S; Yamana H; Horiguchi H; Fushimi K; Sugiura M
PLoS One; 2023; 18(8):e0289950. PubMed ID: 37561756
[TBL] [Abstract][Full Text] [Related]
18. Relationship Between Safety and Cumulative Bevacizumab Dose in Patients With Metastatic Colorectal Cancer Who Received Long-term Bevacizumab Treatment.
Fukuda S; Niisato Y; Tsuji M; Fukuda S; Hagiwara Y; Onoda T; Suzuki H; Tange Y; Yamada T; Yamamoto Y; Moriwaki T
Anticancer Res; 2023 May; 43(5):2085-2090. PubMed ID: 37097650
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab increases risk for severe proteinuria in cancer patients.
Wu S; Kim C; Baer L; Zhu X
J Am Soc Nephrol; 2010 Aug; 21(8):1381-9. PubMed ID: 20538785
[TBL] [Abstract][Full Text] [Related]
20. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
Knijnenburg SL; Mulder RL; Schouten-Van Meeteren AY; Bökenkamp A; Blufpand H; van Dulmen-den Broeder E; Veening MA; Kremer LC; Jaspers MW
Cochrane Database Syst Rev; 2013 Oct; (10):CD008944. PubMed ID: 24101439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
